STOCK TITAN
  1. Home
  2. News
  3. LXRX

Lexicon Pharmaceuticals Inc - LXRX STOCK NEWS

Welcome to our dedicated news page for Lexicon Pharmaceuticals (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lexicon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lexicon Pharmaceuticals's position in the market.

News
Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Rhea-AI Summary
Lexicon Pharmaceuticals announces studies on cost-effectiveness and budget impact of INPEFA at AMCP Nexus 2023 National Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
none
-
News
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
Rhea-AI Summary
INPEFA approved by FDA and listed as preferred product on Medicare formularies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12%
Tags
none
-
News
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Rhea-AI Summary
Tom Garner joins Lexicon Pharmaceuticals as senior vice president and chief commercial officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.41%
Tags
none
News
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
Rhea-AI Summary
INPEFA® (sotagliflozin) approved by FDA for heart failure treatment. New analysis shows it reduces cardiovascular events in patients with left ventricular hypertrophy without hypertension. FDA approval based on Phase 3 studies. Presentation at HFSA Annual Scientific Meeting. Approved for adults with heart failure, type 2 diabetes, chronic kidney disease, and cardiovascular risk factors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
conferences clinical trial
-
News
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Rhea-AI Summary
INPEFA® (sotagliflozin) approved by FDA for heart failure treatment. Upcoming data presentations on LX9211 for diabetic peripheral neuropathic pain. Fast Track designation received. Phase 2b study planned for late-stage development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.38%
Tags
conferences
-
News
Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
Rhea-AI Summary
Lexicon Pharmaceuticals to present at H.C. Wainwright & Co. conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
News
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Rhea-AI Summary
Lexicon Pharmaceuticals announces upcoming scientific presentations on LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP). Phase 2b dose optimization study planning underway, with dosing expected before end of 2023. Fast Track designation received from FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
News
Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023
Rhea-AI Summary
INPEFA approved by FDA for treatment of heart failure. Lexicon Pharmaceuticals to present clinical study results at ESC Congress 2023. INPEFA reduces risk of cardiovascular death and hospitalization in adults with heart failure and type 2 diabetes. Positive impact on stock price expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
conferences clinical trial
-
News
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
Rhea-AI Summary
Lexicon Pharmaceuticals announces that a post hoc analysis of the SOLOIST-WHF Phase 3 outcomes study of sotagliflozin has been published in the Journal of the American College of Cardiology: Heart Failure. The analysis shows that treatment with sotagliflozin resulted in significant risk reductions of approximately 50% for heart failure readmissions and for the composite of cardiovascular death and heart failure readmissions at 30- and 90-days following hospital discharge.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
clinical trial
News
Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
earnings
Stock LXRX logo
Lexicon Pharmaceuticals Inc

Nasdaq:LXRX

LXRX Rankings

#3136 Ranked by Market Cap
#4623 Ranked by Stock Gains
N/A Ranked by Dividends

LXRX Stock Data

485.09M
100.03M
1.67%
82.16%
8.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
The Woodlands

About LXRX

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio